H.R. 2891: Preserve Access to Affordable Generics and Biosimilars Act

117th Congress

To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.

Sponsor: Rep. Jerrold Nadler — D — NY

Authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego rese...

View the full vote history of this bill on GovTrack.us.